To explore how DOCK1 deficiency enhances the anti-tumor effects of metformin, we performed RNA-seq analysis in PLC cells expressing NTC or shDOCK1 (PLC-NTC, PLC-shDOCK1 cells) in the presence or absence of metformin. Here, DOCK1 is linked to neoplasm.